VEGF: a surrogate marker for peripheral vascular disease

Eur J Vasc Endovasc Surg. 2010 Mar;39(3):330-2. doi: 10.1016/j.ejvs.2009.09.025. Epub 2009 Nov 4.

Abstract

This study aims to evaluate the value of VEGF as a surrogate marker for peripheral vascular disease (PVD). Prior to treatment, serum VEGF levels were evaluated by enzyme-linked immunosorbent assay (ELISA) in 293 PVD patients. Risk factors and clinical parameters of PVD were documented. Twenty-six age-matched healthy volunteers served as controls. Serum VEGF values strongly correlated with Fontaine stages (p<0.006, stage IV vs. controls). High VEGF values prior to treatment were associated with poor outcome. Serum VEGF appears to indicate the severity of PVD and might serve as a surrogate indicator of disease severity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Biomarkers / blood
  • Case-Control Studies
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Humans
  • Male
  • Peripheral Vascular Diseases / blood*
  • Predictive Value of Tests
  • Prospective Studies
  • Severity of Illness Index
  • Up-Regulation
  • Vascular Endothelial Growth Factor A / blood*

Substances

  • Biomarkers
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A